4D Molecular Therapeutics, Inc. (FDMT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, 4D Molecular Therapeutics, Inc. reported revenue of $85.21M, up 230194.6% from the prior year. The company ran a net loss, with a net margin of -164.4%. It held $566.71M in total assets against $61.05M in total liabilities.
Key ratios (FY2025)
-187.2%
Operating margin
-164.4%
Net margin
-27.7%
Return on equity
+230194.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $85.21M | $37.0K | $20.72M | $3.13M | $18.04M | $13.36M | $6.96M | — |
| Operating Income | -$159.55M | -$187.84M | -$112.87M | -$110.03M | -$71.33M | -$56.66M | -$50.76M | — |
| Net Income | -$140.11M | -$160.87M | -$100.84M | -$107.49M | -$71.32M | -$56.69M | -$49.31M | — |
| EPS (Diluted) | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 | — | — | — |
| Total Assets | $566.71M | $560.38M | $339.89M | $261.85M | $353.49M | $288.33M | $58.23M | — |
| Total Liabilities | $61.05M | $49.78M | $32.06M | $30.51M | $34.38M | $31.94M | $28.22M | — |
| Shareholders' Equity | $505.66M | $510.61M | $307.83M | $231.34M | $319.11M | $256.39M | -$72.97M | -$27.59M |
| Cash & Equivalents | $60.24M | $149.34M | $249.11M | $52.35M | $153.00M | $276.73M | $49.65M | — |
| Operating Cash Flow | -$109.08M | -$134.59M | -$75.79M | -$86.69M | -$69.13M | -$50.91M | -$36.71M | — |
| Capital Expenditures | $536.0K | $3.79M | $2.77M | $11.54M | $9.11M | $1.00M | $3.20M | — |
| Shares Outstanding | 57.61M | 45.79M | 43.08M | 32.63M | 32.22M | 26.68M | 5.18M | — |